Indefinite Delivery Contract SPE2DX15D9756

This indefinite delivery contract (IDC) was awarded by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The single-award IDC, valued at up to $499,999,999 through December 2025, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. These products are used to support the recurring medical supply needs of military health facilities worldwide under the DLA's SPE2DB program.

The delivered pharmaceutical and medical products span a diverse set of categories, such as injections, tablets, creams, auto-injectors, and specialty medications. Notable items include Xolair, Trikafta, Keytruda, Botox, Nucala, Nexplanon, Mirena, Exparel, and various other prescription drugs and medical supplies. The contract does not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.